

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-21. (Canceled)

22. (Currently Amended) A method for treating leukemia, comprising selecting a patient in need thereof and administering to a patient in need thereof an effective amount of ~~an~~ a humanized anti-human VEGF receptor Flt-1 antibody which has antibody-dependent cellular cytotoxic activity against leukemia cells.

Claim 23. (Canceled)

24. (Currently Amended) The method according to claim 22, wherein the humanized anti-human VEGF receptor Flt-1 antibody is an antibody comprising complementarity determining regions of an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

Claims 25. (Canceled)

26. (Currently Amended) The method according to claim 22, wherein the humanized anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')₂, F(ab')₂, a single chain antibody and a disulfide stabilized antibody.

27. (Currently Amended) The method according to claim 22, wherein the humanized anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope or a protein or a low molecular weight anticancer agent by a chemical or genetic engineering means.

Claim 28. (Canceled)

29. (Currently Amended) A method for treating leukemia, comprising selecting a patient in need thereof and administering to the patient an effective amount of a human chimeric anti-human VEGF receptor Flt-1 antibody which has antibody-dependent cellular cytotoxic activity against leukemia cells.

30. (Previously Presented) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody which belongs to the IgG type.

31. (Previously Presented) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody which belongs to the IgG1 type.

32. (New) The method according to claim 29, wherein the human chimeric anti-human VEGF receptor Flt-1 antibody is an antibody comprising a variable region heavy

chain and a variable region light chain of an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.